EVALUATED ON CLINICAL FEATURE, SUB-CLINICAL OF NONALCOHOLIC FATTY LIVER DISEASE

Nguyễn Công Long1,, Nguyễn Thanh Nam1
1 Department of Gastroenterology and Hepatology, Bach Mai Hospital

Main Article Content

Abstract

Objectives: The aim of this study was the evaluation of clinical features and subclinical of nonalcoholic fatty liver disease (NAFLD) Method: A total of 50 patients were enrolled with nonalcoholic fatty liver disease from 01/2019 to7/2020 in Bachmai hospital. Results: Mean age at diagnosis was 47 years, 23(45.1%) were male. Common clinical symptoms are fatigue, dyspepsia, abdomial pain accounted for 58.8%), 35.3% and 13.7%, respectively. 100% of patients had very high elevation of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and GGT. In addition, the majority of patients had metabolic syndrome such as Hypertriglyceridemia (80%) and low HDL (8%). The diabetes rate was 13.7%. Conclusion: diagnosed NAFLD patients is higher in young age. The most common symptoms is fatigue and elevated aminotransferase.

Article Details

References

1. Anstee, Q.M., et al., From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol, 2019. 16(7): p. 411-428.
2. Wong, V.W. and H.L. Chan, Transient elastography. J Gastroenterol Hepatol, 2010. 25(11): p. 1726-31.
3. Saydah, S.H., et al., Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol, 2003. 157(12): p. 1092-100.
4. Ioannou, G.N., et al., Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterology, 2003. 125(4): p. 1053-9.
5. Malik, S., et al., Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation, 2004. 110(10): p. 1245-50.
6. Eriksson, K.F. and F. Lindgärde, No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with diet and exercise. Diabetologia, 1998. 41(9): p. 1010-6.